Gemtuzumab as Part of Chemotherapy
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 270 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Antibody Drug Conjugate (ADC), Chemotherapy, Hypomethylating Agents (HMA), White Blood Cell Stimulant, CD33
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1564
- NCT Identifier
- NCT00801489
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.